Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1978 Oct;64(2):193–200. doi: 10.1111/j.1476-5381.1978.tb17289.x

beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine.

D W Costain, A R Green
PMCID: PMC1668317  PMID: 30503

Abstract

1 The effect of various beta-adrenoceptor blocking agents on the 5-hydroxytryptamine (5-HT)-induced hyperactivity response produced in rats by administration of tranylcypromine (10 mg/kg i.p.) followed by L-tryptophan (50 mg/kg i.p.) has been investigated. 2 (+/-)-Alprenolol, (+/-)-timolol, (+/-)-sotalol, (+/-)-pindolol (all at 40 mg/kg) all inhibited the hyperactivity response to some degree when given 45 min before the tranylcypromine, as did (+/-)-oxprenolol when given after the L-tryptophan. 3 beta-Adrenoceptor antagonists that are not found in the brain appreciable amount after peripheral injection, (+/-)-atenolol, (+/-)-practolol, (+/-)-labetalol and (+/-)-acebutalol, did not inhibit the 5-HT-mediated behaviour. 4 Neither the beta1-selective drug (+/-)-metoprolol, nor the beta2-selective drug (+/-)-butoxamine inhibited the behavioral response. 5 The drugs that blocked the 5-HT-mediated behaviour did not alter brain 5-HT concentrations, synthesis rate or the accumulation of 5-HT following tranylcypromine/L-tryptophan. However, they did inhibit the hyperactivity produced by the suggested 5-HT agonist, 5-methoxy N,N-dimethyltryptamine, indicating that the beta-adrenoceptor blocking drugs were inhibiting the post-synaptic 5-HT-mediated response. 6 Circling produced by methamphetamine (3 mg/kg) in unilateral nigro-striatal lesioned rats was not altered by alprenolol, sotalol, pindolol or metaprolol, indicating that these drugs do not alter dopamine-mediated behaviour. 7 It is concluded that non-selective (beta1 and beta2) adrenoceptor antagonists which have a high brain/blood ratio following their peripheral injection, block 5-HT-mediated behavioural responses in the rat.

Full text

PDF
193

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablad B., Borg K. O., Carlsson E., EK L., Johnson G., Malmfors T., Regårdh C. G. A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):7–23. doi: 10.1111/j.1600-0773.1975.tb03318.x. [DOI] [PubMed] [Google Scholar]
  2. Bodin N. O., Borg K. O., Johansson R., Obianwu H., Svensson R. Absorption, distribution and excretion of alprenolol in man, dog and rat. Acta Pharmacol Toxicol (Copenh) 1974 Oct;35(4):261–269. doi: 10.1111/j.1600-0773.1974.tb00745.x. [DOI] [PubMed] [Google Scholar]
  3. Bodin N. O., Borg K. O., Johnansson R., Ramsay C. H., Skänberg I. Tissue distribution of metoprolol-(3-h) in the mouse and the rat. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):116–124. doi: 10.1111/j.1600-0773.1975.tb03328.x. [DOI] [PubMed] [Google Scholar]
  4. Collins R. F. Pharmacocinétique de l'acébutolol. Nouv Presse Med. 1975 Dec 31;4(46 Suppl):3223–3228. [PubMed] [Google Scholar]
  5. Curzon G., Green A. R. Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol. 1970 Jul;39(3):653–655. doi: 10.1111/j.1476-5381.1970.tb10373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deakin J. F., Green A. R. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol. 1978 Oct;64(2):201–209. doi: 10.1111/j.1476-5381.1978.tb17290.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor. Nature. 1977 May 19;267(5608):289–290. doi: 10.1038/267289a0. [DOI] [PubMed] [Google Scholar]
  8. Garvey H. L., Ram N. Centrally induced hypotensive effects of beta-adrenergic blocking drugs. Eur J Pharmacol. 1975 Sep-Oct;33(2):283–294. doi: 10.1016/0014-2999(75)90172-7. [DOI] [PubMed] [Google Scholar]
  9. Grahame-Smith D. G. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol. 1971 Dec;43(4):856–864. doi: 10.1111/j.1476-5381.1971.tb07222.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Grahame-Smith D. G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem. 1971 Jun;18(6):1053–1066. doi: 10.1111/j.1471-4159.1971.tb12034.x. [DOI] [PubMed] [Google Scholar]
  11. Green A. R., Grahame-Smith D. G. (-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature. 1976 Aug 12;262(5569):594–596. doi: 10.1038/262594a0. [DOI] [PubMed] [Google Scholar]
  12. Green A. R., Grahame-Smith D. G. The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology. 1974 Nov;13(10-11):949–959. doi: 10.1016/0028-3908(74)90086-0. [DOI] [PubMed] [Google Scholar]
  13. Haigler H. J., Aghajanian G. K. Peripheral serotonin antagonists: failure to antagonize serotonin in brain areas receiving a prominent serotonergic input. J Neural Transm. 1974;35(4):157–273. doi: 10.1007/BF02205223. [DOI] [PubMed] [Google Scholar]
  14. Haigler H. J., Aghajanian G. K. Serotonin receptors in the brain. Fed Proc. 1977 Jul;36(8):2159–2164. [PubMed] [Google Scholar]
  15. Hayes A., Cooper R. G. Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. J Pharmacol Exp Ther. 1971 Feb;176(2):302–311. [PubMed] [Google Scholar]
  16. Heal D. J., Green A. R., Boullin D. J., Grahame-Smith D. G. Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa. Psychopharmacology (Berl) 1976 Sep 29;49(3):287–300. doi: 10.1007/BF00426832. [DOI] [PubMed] [Google Scholar]
  17. Iversen L. L. Dopamine receptors in the brain. Science. 1975 Jun 13;188(4193):1084–1089. doi: 10.1126/science.2976. [DOI] [PubMed] [Google Scholar]
  18. Martin L. E., Hopkins R., Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):695–710. [PubMed] [Google Scholar]
  19. Neff N. H., Tozer T. N. In vivo measurement of brain serotonin turnover. Adv Pharmacol. 1968;6(Pt A):97–109. doi: 10.1016/s1054-3589(08)61160-6. [DOI] [PubMed] [Google Scholar]
  20. Scales B., Cosgrove M. B. The metabolism and distribution of the selective adrenergic beta blocking agent, practolol. J Pharmacol Exp Ther. 1970 Nov;175(2):338–347. [PubMed] [Google Scholar]
  21. Schechter Y., Weinstock M. Beta-adrenoceptor blocking agents and responses to adrenaline and 5-hydroxytryptamine in rat isolated stomach and uterus. Br J Pharmacol. 1974 Oct;52(2):283–287. doi: 10.1111/j.1476-5381.1974.tb09711.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tocco D. J., Duncan A. E., Delauna F. A., Hucker H. B., Gruber V. F., Vandenheuvel W. J. Physiological disposition and metabolism of timolol in man and laboratory animals. Drug Metab Dispos. 1975 Sep-Oct;3(5):361–370. [PubMed] [Google Scholar]
  23. Weinstock M., Schechter Y. Antagonism by propranolol of the ganglion stimulant action of 5-hydroxytryptamine. Eur J Pharmacol. 1975 Jun-Jul;32(02):293–301. doi: 10.1016/0014-2999(75)90296-4. [DOI] [PubMed] [Google Scholar]
  24. Weinstock M., Weiss C., Gitter S. Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists. Neuropharmacology. 1977 Apr;16(4):273–276. doi: 10.1016/0028-3908(77)90106-x. [DOI] [PubMed] [Google Scholar]
  25. Yorkston N. J., Zaki S. A., Malik M. K., Morrison R. C., Havard C. W. Propranolol in the control of schizophrenic symptoms. Br Med J. 1974 Dec 14;4(5945):633–635. doi: 10.1136/bmj.4.5945.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yorkston N. J., Zaki S. A., Pitcher D. R., Gruzelier J. H., Hollander D., Sergeant H. G. Propranolol as an adjunct to the treatment of schizophrenia. Lancet. 1977 Sep 17;2(8038):575–578. doi: 10.1016/s0140-6736(77)91427-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES